# Research Idea Ranking

**Generated:** 2026-01-21T16:09:27.700183
**Model:** gpt-5.2 (reasoning: high)
**Tokens:** 8562
**OpenAI Response ID:** resp_0500fdd204dffd47006970ebc24afc8195a1e5858817b010d6

---

### Rankings

**#1: State Insulin Price Caps and Diabetes Management Outcomes**
- **Score: 74/100**
- **Strengths:** Strong policy relevance and a genuinely under-studied *outcome margin* (health utilization/A1c), not just prices. Enough treated states to support modern staggered-adoption DiD with reasonable inference.
- **Concerns:** The biggest threat is **contamination from national changes** (Medicare $35 cap in 2023; manufacturer voluntary caps in 2024) that may differentially affect states and insurers. Data access (HCUP SID) is costly and outcome definitions/payer splits must be handled carefully.
- **Novelty Assessment:** Moderately high novelty: there are emerging papers on OOP spending/claims impacts, but far fewer (if any) credible papers on downstream health outcomes attributable to state caps.
- **DiD Assessment:**
  - Pre-treatment periods: **Strong**
  - Selection into treatment: **Marginal**
  - Comparison group: **Strong**
  - Treatment clusters: **Strong** (≈20+ treated)
  - Concurrent policies: **Marginal** (national Medicare/manufacturer changes—needs sample restrictions, payer stratification, or endpoint choices)
- **Recommendation:** **PURSUE**

---

**#2: Universal Free School Meals and Household Food Security**
- **Score: 48/100**
- **Strengths:** High policy salience and a clean, directly-measured outcome in HPS (food insufficiency in households with children). The timing (post–COVID waivers) is potentially informative, and the question is not yet saturated with causal work.
- **Concerns:** Under the institute’s checklist, the design is fragile because there are **too few treated states (8)** and only ~2.5 years of pre-period in HPS for the earliest adopters—limited ability to validate pre-trends. Inference with 8 treated clusters is precarious; you’d need a compelling small-cluster strategy (randomization inference/permutation tests) and/or a redesign (e.g., triple-diff using households without children, intensity designs).
- **Novelty Assessment:** High novelty on *causal identification* with modern staggered DiD/event studies; most existing outputs are descriptive or implementation-focused.
- **DiD Assessment:**
  - Pre-treatment periods: **Marginal** (HPS starts 2020; earliest treatment 2022)
  - Selection into treatment: **Marginal**
  - Comparison group: **Strong**
  - Treatment clusters: **Weak** (8 treated states)
  - Concurrent policies: **Marginal** (SNAP emergency allotments ending; other pandemic-era unwind)
- **Recommendation:** **SKIP (as currently designed)** — only upgrade to **CONSIDER** if you pre-specify a credible small-treated-cluster inference plan and/or a design that increases usable treatment variation.

---

**#3: State Paid Family Leave and Maternal Labor Force Participation**
- **Score: 46/100**
- **Strengths:** Good data (CPS ASEC) and a classic, policy-relevant question with clear labor-supply outcomes. Long pre-periods exist for most treated states, enabling richer event studies.
- **Concerns:** This area is **crowded** (especially CA/NJ) and—critically by your checklist—there are **<10 treated operational programs through 2024**, making state-cluster inference fragile and leaving results sensitive to specification. Also, other contemporaneous changes affecting mothers (childcare markets, ACA-era changes, pandemic labor shifts) complicate interpretation.
- **Novelty Assessment:** Low-to-medium: paid leave is heavily studied; incremental novelty mainly comes from post-2018 adopters, but that wave is still small-N for treatment clusters.
- **DiD Assessment:**
  - Pre-treatment periods: **Strong**
  - Selection into treatment: **Marginal**
  - Comparison group: **Strong**
  - Treatment clusters: **Weak** (≈9 treated operational by 2024 in your list)
  - Concurrent policies: **Marginal**
- **Recommendation:** **SKIP (in this form)** — becomes more viable if broadened to more treated “units” (e.g., sub-state variation or additional comparable leave reforms) or paired with designs explicitly built for small treated-cluster settings.

---

**#4: State Data Privacy Laws and Tech Sector Employment**
- **Score: 38/100**
- **Strengths:** Novel and timely for federal privacy debates; QCEW is accessible and high-frequency. If identified cleanly, this could be a real contribution because employment effects are not the usual focus in privacy-law research.
- **Concerns:** As proposed, **California’s 2020 implementation is co-timed with COVID**, a major dealbreaker for clean attribution at the most salient “first mover.” Also, treated states are systematically tech-heavy (selection/comparison issues), and the tech sector experienced large national shocks (2022–2024 downturn, remote-work re-sorting) that may not be absorbed by simple time FE.
- **Novelty Assessment:** High on the outcome (employment), but novelty cannot compensate for weak identification.
- **DiD Assessment:**
  - Pre-treatment periods: **Strong**
  - Selection into treatment: **Marginal**
  - Comparison group: **Marginal** (tech intensity differs sharply)
  - Treatment clusters: **Strong** (by 2025, many adopters)
  - Concurrent policies: **Weak** (COVID coincident with the flagship early adoption; additional sector-wide shocks)
- **Recommendation:** **SKIP** — could be reconsidered only if you **drop CA entirely** and reframe around the 2023+ wave with a border-county or matched-industry approach and explicit handling of tech-cycle shocks.

---

**#5: Clean Slate Laws and Employment Among Formerly Incarcerated Individuals**
- **Score: 30/100**
- **Strengths:** Important policy question; Clean Slate is meaningfully different from “ban-the-box” and plausibly has larger labor-market effects.
- **Concerns:** The proposed outcome strategy is not credible: **CPS ASEC does not identify criminal records**, and demographic proxies (e.g., young Black men) are too noisy and confounded to interpret as effects on the target population. Additionally, many laws have long implementation lags, leaving **few operational treated states** in the usable window.
- **Novelty Assessment:** Medium: Clean Slate specifically is less studied than ban-the-box, but the empirical question has been approached in related forms; the binding constraint here is measurement, not novelty.
- **DiD Assessment:**
  - Pre-treatment periods: **Strong**
  - Selection into treatment: **Marginal**
  - Comparison group: **Strong**
  - Treatment clusters: **Weak** (operational treated states likely <10 for years)
  - Concurrent policies: **Marginal** (ban-the-box and other reentry policies overlap)
- **Recommendation:** **SKIP** — this only becomes promising with **administrative expungement + UI wage records** (or another dataset that directly identifies affected individuals).

---

### Summary

Only the **insulin price cap → health outcomes** project clears the bar as a strong “PURSUE” given novelty, adequate treated-cluster count, and feasible outcomes (especially if you pre-plan how to handle 2023–2024 national confounders via payer splits and sample windows). Several other ideas are interesting and policy-relevant, but **fail the checklist on treated-cluster count or are undermined by major confounding (COVID/tech shocks) or weak measurement (Clean Slate)**—they should be redesigned before investing serious resources.